The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Thyroid dysfunction and immune checkpoint inhibitor outcomes.
 
Mitchell S. von Itzstein
No Relationships to Disclose
 
Rong Lu
No Relationships to Disclose
 
Sadia Ali
Consulting or Advisory Role - Array BioPharma (I); Boston Biomedical (I); Ipsen (I)
Speakers' Bureau - Bristol-Myers Squibb (I); Ipsen (I)
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmuneSensor Therapeutics (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)
 
Donglu Xie
No Relationships to Disclose
 
Jennifer Cai
No Relationships to Disclose
 
Yang Xie
No Relationships to Disclose
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Samsung Bioepis
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending: “Prediction and Treatment of Immunotherapeutic Toxicity” (provisional, application number 62/461,455) (Inst); Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.